A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study
Journal article published in 2016 by
Graham R. Foster,
Alex J. Thompson,
Peter J. Ruane,
Sergio M. Borgia,
Gregory Dore,
Kimberly Workowski,
Robert H. Hyland,
Jing Wang,
Evguenia S. Svarovskaia,
Luisa M. Stamm,
Diana M. Brainard,
Mani Subramanian,
John G. McHutchison,
Thomas Berg,
Kosh Agarwal 
and other authors.
and other authors.
